Side Effects of Abilify (Aripiprazole)
Abilify causes a range of side effects that require careful monitoring, with the most serious being neuroleptic malignant syndrome, tardive dyskinesia, metabolic disturbances (hyperglycemia, dyslipidemia, weight gain), and unusual compulsive urges including pathological gambling and hypersexuality. 1
Serious and Life-Threatening Side Effects
Neurological Emergencies
- Neuroleptic Malignant Syndrome (NMS): High fever, muscle rigidity, confusion, sweating, and changes in pulse/heart rate/blood pressure. This is a rare but potentially fatal condition requiring immediate medical attention 1
- Tardive Dyskinesia: Uncontrolled movements of face, tongue, or other body parts that may be irreversible even after stopping the medication 1
- Seizures (convulsions) 1
Cardiovascular Risks
- Orthostatic hypotension: Lightheadedness or fainting when rising from sitting/lying position 1
- Stroke risk in elderly patients with dementia-related psychosis, which can lead to death 1
- Falls: Due to sleepiness, dizziness, blood pressure changes, and slowed thinking/motor skills 1
Metabolic Complications
The 2025 INTEGRATE guidelines emphasize that cardiometabolic monitoring is crucial 2:
- Hyperglycemia and diabetes: Can lead to coma or death if severe. Monitor fasting glucose at baseline, at 4 weeks, then at 3 months and annually 2, 1
- Dyslipidemia: Increased cholesterol and triglycerides. Recent 2024 data shows LDL increases by 0.06 mmol/L and HDL by 0.02 mmol/L per 5 mg dose increment 3
- Weight gain: Check BMI and waist circumference weekly for 6 weeks, then at 3 months and annually 2. Doses >7% weight gain over one year show 30% increased odds per 5 mg dose increase 3
Behavioral and Impulse Control Disorders
A critical and underrecognized side effect:
- Compulsive behaviors: Pathological gambling, binge eating, compulsive shopping, hypersexuality, and kleptomania 1, 4
- A 2024 systematic review found these symptoms appear within 30 days of starting aripiprazole in 71% of cases, affecting males more frequently, at average doses of only 11.63 mg daily 4
- These urges resolve within 30 days of discontinuation or dose reduction 4
- The FDA issued warnings about this in 2016 5
Hematologic
- Low white blood cell count 1
Common Side Effects
In Adults (occurring in >5% of patients):
- Nausea
- Vomiting
- Constipation
- Headache
- Blurred vision
- Upper respiratory illness
- Dizziness
- Anxiety
- Insomnia
- Restlessness
- Akathisia (inner sense of restlessness/need to move) 1
The 2025 INTEGRATE guidelines note akathisia can be managed with dose reduction, switching to quetiapine or olanzapine, or adjunctive propranolol 10-30 mg two to three times daily 2.
In Children and Adolescents:
- Feeling sleepy
- Headache
- Vomiting
- Fatigue
- Increased or decreased appetite
- Increased saliva/drooling
- Insomnia
- Nausea
- Stuffy nose
- Weight gain
- Uncontrolled movements (restlessness, tremor, muscle stiffness) 1
A 2016 Danish study of pediatric patients reported severe adverse events including chronic insomnia, Parkinsonism, behavioral changes, psychoses, anxiety, convulsions, and neuroleptic malignant syndrome 6.
Important Clinical Considerations
Dose-Related Effects
Recent 2024 evidence shows dose-dependent metabolic effects 3:
- Higher doses cause greater initial weight gain (first 5 months)
- After 5 months, lower doses paradoxically associate with greater weight gain
- Use minimum effective doses, particularly in the first 5 months
Hyperprolactinemia Management
When aripiprazole is used as augmentation therapy, the 2025 INTEGRATE guidelines note it can actually reduce hyperprolactinemia caused by other antipsychotics, as aripiprazole is a D2 partial agonist 2, 7. This is a beneficial effect when combined with high-prolactin antipsychotics.
Temperature Regulation
Difficulty controlling body temperature, especially with exercise or heat exposure. Patients must maintain adequate hydration 1.
Other Risks
- Difficulty swallowing (aspiration risk) 1
- Cognitive impairment (though evidence is mixed and may relate more to total antipsychotic dose burden) 7
Critical Monitoring Protocol
Based on 2025 INTEGRATE guidelines 2:
- Baseline: BMI, waist circumference, blood pressure, HbA1c, fasting glucose, lipids, prolactin, liver function, renal function, CBC, ECG
- Week 1-6: Weekly BMI, waist circumference, blood pressure
- Week 4: Repeat fasting glucose
- Month 3: Repeat all baseline measures
- Annually: Repeat all baseline measures
Key Clinical Pitfall
The most commonly overlooked side effect is compulsive/impulsive behaviors 4, 5. Screen all patients for gambling, shopping, eating, and sexual urges before starting aripiprazole and at each follow-up, particularly in the first month. Patients with pre-existing impulse control issues are at higher risk but even those without prior history can develop these behaviors 4.